Revolutionizing Biomarker Discovery with a Excessive-Throughput Immunoproteomic Platform
BOSTON, July 30, 2024 /PRNewswire/ — Sengenics Company LLC is proud to announce the launch of i-Ome Most cancers, a cutting-edge analysis instrument designed to remodel most cancers biomarker discovery utilizing only a drop of blood.
i-Ome Most cancers marks a big leap ahead in immunoproteomics, offering a speedy and cost-effective strategy to characterize the immune system’s response to most cancers. Most cancers is intently related to protein alterations, which might stimulate the manufacturing of autoantibodies. i-Ome Most cancers capitalizes on this relationship, enabling the direct identification of disease-associated proteins, providing essential insights into this devastating illness and its therapy.
By facilitating high-throughput screening of autoantibodies, i-Ome Most cancers leverages Sengenics’s proprietary KREX® know-how to ship distinctive specificity for sturdy and biologically related quantitative outcomes, streamlining the biomarker discovery pipeline.
“Autoantibody profiling with i-Ome Most cancers has wide-ranging functions, from enabling services for earlier diagnoses to guiding the event of most cancers vaccines and therapies,” stated Dr. Jonathan Blackburn, Founder and Chief Scientific Officer of Sengenics. “For instance, i-Ome Most cancers can reveal how most cancers therapies would possibly induce the immune system to reinforce therapeutic efficacy or doubtlessly trigger severe uncomfortable side effects.”
The i-Ome Most cancers platform contains a targeted library of over 500 expertly curated proteins which can be identified to be autoantigenic in cancers, together with these continuously mutated in most cancers or concerned in key most cancers signaling pathways. This newest innovation can display twice as many autoantibodies as its predecessor, reinforcing Sengenics’s dedication to advancing most cancers analysis.
Dr. Jessica Da Gama Duarte, a senior postdoctoral analysis fellow on the Olivia Newton-John Most cancers Analysis Institute, said, “I am excited in regards to the expansive most cancers content material of i-Ome Most cancers. It’ll allow autoantibody profiling throughout a bigger tumor antigen repertoire, considerably enhancing the probabilities of figuring out related most cancers biomarkers.”
Famend for its high-quality requirements, i-Ome Most cancers upholds Sengenics’s repute for industry-leading reproducibility and specificity. The platform is now obtainable by means of service suppliers globally, able to speed up the way forward for most cancers precision medication.
Disclaimer: i-Ome Most cancers is for analysis use solely and isn’t supposed for diagnostic functions.
About Sengenics
Sengenics Company LLC, a useful proteomics firm, is dedicated to advancing precision medication by empowering researchers with biologically related and actionable immunoproteomic insights throughout a broad spectrum of ailments. On the coronary heart of its mission, Sengenics presents superior, high-throughput instruments utilizing proprietary know-how to exactly detect autoantibody biomarkers and protein interactions for fundamental, translational, and medical analysis. Its sturdy instruments have been leveraged by prime pharmaceutical corporations and main analysis establishments to reinforce illness understanding and streamline the biomarker pipeline. Sengenics is headquartered within the U.S. and has a worldwide community of workplaces, distributors, and repair suppliers.
SOURCE Sengenics
